In this episode of "In the Interim…", Dr. Scott Berry talks with Dr. Alun Bedding, a professional certified coach and statistician who spent decades in pharmaceutical statistics, including as global head of statistical methods, collaboration, and outreach at Roche, before founding his own coaching and consulting practice.

In this episode of “In the Interim…,” Dr. Scott Berry talks with Dr. Roger Lewis, Dr. Anna McGlothlin, and Dr. Nick Berry — all co-authors on the CHIPS trial results recently published in JAMA (Spinella et al., August 2026) — about the design, implementation, and results.

Berry Consultants is excited to share a short video highlighting members of our team and their planned presentations at the upcoming ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (RISW) in Rockville, Maryland, September 16-18, 2026.

In this episode of "In the Interim…", Dr. Scott Berry examines three recent health-research headlines through a statistician's lens: an Adventist Health Study-2 analysis, an Emory University trial, and a British Medical Journal study.

In this episode of "In the Interim...", Dr. Scott Berry dissects prevailing concepts of “clinically meaningful difference” in clinical trials focusing on progressive diseases.

Designing a group sequential phase 3 with a long time to final endpoint, using longitudinal modelling and Bayesian predictive probabilities for decision making at the interims.